Studies on animals and humans have demonstrated the IL-23/IL-17 association as a potential therapeutic target for various autoimmune diseases, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), and RA [221,226,227]. This evidence concerns the gene IL23A and psoriatic arthritis.